Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.5K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

5.8K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flexible active-matrix micro-LED display with 1T-1FeMFET architecture featuring scaling-limit-free design.

Nature communications·2026
Same author

Deuterium modification of tyrosine kinase inhibitors contributes to reversing ferroptosis resistance through upregulation of aldehyde oxidase 1 in hepatocellular carcinoma.

Acta pharmaceutica Sinica. B·2026
Same author

CXCL8/SDC1 axis mediates tumor stem cell interactions to drive remote transfer in thyroid cancer.

Journal of pharmaceutical analysis·2026
Same author

ERBB3 blockade sensitizes hepatocellular carcinoma to regorafenib after first-line tyrosine kinase inhibitor resistance by inhibiting HIF1A-ABCB1 signaling.

Clinical and molecular hepatology·2026
Same author

Integrative methylation and transcriptomic analysis reveals key genes linking cellular senescence and metabolic reprogramming in colorectal liver metastasis.

Bioscience trends·2025
Same author

Toward accurate single image sand dust removal by utilizing uncertainty-aware neural network.

Frontiers in neurorobotics·2025

Related Experiment Video

Updated: Oct 4, 2025

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.3K

Super-enhancers modulate interleukin-6 expression and function in cancers.

Yuhua Bao1,2, Yingcheng Wu3, Baorui Tao3

  • 1Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Translational Cancer Research
|February 4, 2022
PubMed
Summary
This summary is machine-generated.

This study reveals that super-enhancers, specifically IL6-SEa, are crucial for interleukin 6 (IL-6) production in cancer cells. Targeting these elements significantly reduces IL-6 expression and cancer cell proliferation.

Keywords:
BRD4IL-6pancreatic cancersuper-enhancers

More Related Videos

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.9K
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

7.7K

Related Experiment Videos

Last Updated: Oct 4, 2025

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.3K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.9K
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

7.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Interleukin 6 (IL-6) is a key inflammatory cytokine implicated in cancer development and progression.
  • The precise mechanisms regulating IL-6 production within the tumor microenvironment remain incompletely understood.

Purpose of the Study:

  • To investigate the role of super-enhancers in regulating IL-6 expression in cancer.
  • To identify specific regulatory elements responsible for IL-6 production.

Main Methods:

  • Bioinformatic analysis and quantitative real-time PCR (RT-PCR) were employed to assess IL-6 expression.
  • Super-enhancers of IL-6 were mapped using sgRNAs, and knockout cells were generated.
  • Cell proliferation and colony formation assays were performed.
  • ATAC-seq analysis was utilized to correlate super-enhancers with IL-6 expression.

Main Results:

  • IL-6 expression was found to be elevated in multiple cancers, notably pancreatic cancer (PAAD).
  • Inhibitors of super-enhancers significantly reduced IL-6 expression in various cancer cell lines.
  • A critical super-enhancer, IL6-SE, comprising IL6-SEa and IL6-SEb, was identified; genetic deletion of IL6-SEa markedly decreased IL-6 expression and impaired cancer cell proliferation.
  • Epigenetic activation of IL6-SEa correlated with IL-6 expression in patients.

Conclusions:

  • IL-6 expression in cancer is dependent on super-enhancers.
  • IL6-SEa is identified as a critical DNA regulatory element controlling IL-6 expression.
  • These findings offer novel insights into the epigenetic regulation of IL-6 in cancer.